Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Journal of Biopharmaceutical Statistics|July 9, 2008
Accounting for interim safety monitoring of an adverse event upon termination of a clinical trialMichael J DallasComputer Methods and Programs in Biomedicine|May 22, 2003
Computing P-values for a class of permutation tests of equal survival functionsMichael J Dallas, P V RaoPharmaceutical Statistics|November 10, 2010
Assessing non-inferiority to an aggregate response with an application to development of pneumococcal conjugate vaccinesYi Pan, Guanghan F Liu, Michael J DallasClinical Trials (London, England)|April 1, 2008
Evaluating the safety of a rotavirus vaccine: the REST of the storyJoseph F Heyse, Barbara J Kuter, Michael J Dallas, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 8, 2008
The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccinePenelope H Dennehy, Michelle G Goveia, Michael J Dallas, et al.The Pediatric Infectious Disease Journal|June 4, 2008
Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequencyMichelle G Goveia, Mark J DiNubile, Michael J Dallas, et al.The Pediatric Infectious Disease Journal|December 2, 2009
Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between dosesMichelle G Goveia, Leora Suprun, Robbin F Itzler, et al.The Pediatric Infectious Disease Journal|November 29, 2007
Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infantsMichelle G Goveia, Zoe M Rodriguez, Michael J Dallas, et al.The Pediatric Infectious Disease Journal|May 9, 2007
Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United StatesZoe M Rodriguez, Michelle G Goveia, Jon E Stek, et al.Human Vaccines|March 29, 2011
Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen)Penelope H Dennehy, Timo Vesikari, David O Matson, et al.Pageof 3